Hyperbaric oxygen therapy (HBOT) is not standard cardiac care. It has been studied for heart conditions since the 1960s, yet it appears in no cardiology guideline and is not FDA-approved for heart disease. The most concrete recent signal is a 2025 meta-analysis of three small studies (195 patients) showing a 4.16% average gain in left ventricular ejection fraction after revascularization. The evidence remains early and off-label, worth understanding honestly rather than acting on alone.
How Does HBOT Affect the Heart?
HBOT raises the amount of oxygen dissolved in blood plasma, bypassing the usual hemoglobin-based delivery, which is why it has been proposed for tissue that is short on oxygen. Cardiovascular disease reduces oxygen supply to the heart muscle: narrowed coronary arteries limit flow, and in heart failure low cardiac output affects perfusion throughout the body. When supply falls below demand, heart muscle deteriorates and cells can die. The heart is one of many organs affected by chronic disease, and our resource on HBOT for chronic conditions covers the wider set.
There is a catch specific to the heart. High oxygen tension can cause mild vasoconstriction in normal coronary arteries, and hyperoxia measurably affects diastolic myocardial and endothelial function (Wunderlich et al., 2017). So more oxygen is not automatically better for cardiac tissue, and HBOT for heart conditions calls for careful patient selection rather than routine use.
HBOT and Cardiac Conditions: Evidence and Status
| Cardiac condition | Evidence level | Status in practice |
|---|---|---|
| Acute myocardial infarction | Emerging (older adjunct trials) | Not in standard protocols; stenting dominates |
| Chronic heart failure | Limited (no completed large RCT) | Investigational only |
| Post-cardiac-surgery healing | Limited (small studies) | Occasional adjunct for wound complications |
| Atherosclerosis | Limited (speculative) | Not supported |
| PAD-related wounds | Moderate (distinct from cardiac use) | Used for non-healing ischemic wounds |
Can HBOT Help After a Heart Attack?
The cardiac research with actual trial data centers on the period during and after a heart attack, but it has not changed practice. Early laboratory and clinical work suggested HBOT during the acute phase could reduce infarct size and support surviving heart muscle. The clearest human trial is the HOT-MI study (Stavitsky et al., 1998), which combined HBOT with thrombolysis in myocardial infarction and reported functional signals, but it was small and predates modern reperfusion care.
The more recent evidence is the 2025 Br J Cardiol meta-analysis (Putra Pramana et al.), which pooled three studies of 195 patients and found HBOT after revascularization raised ejection fraction by 4.16% (95% CI 0.97 to 7.34, p=0.01). Notably, it found no significant change in end-diastolic or end-systolic volumes, so the benefit was narrow. HBOT is not part of acute heart-attack care, partly because catheter-based reperfusion (stenting) is highly effective and immediately available, and coordinating a chamber with emergency cardiac care is logistically difficult.
Can HBOT Help Heart Failure?
No completed large randomized trial supports HBOT for chronic heart failure, so any use is investigational. The proposed mechanisms, better myocardial oxygenation, reduced inflammation, and angiogenesis in ischemic tissue, are plausible, but the human data is thin and uncontrolled. Modern heart-failure therapy has strong mortality evidence behind it: ACE inhibitors and ARBs, beta-blockers, SGLT2 inhibitors, and MRAs, plus device therapy for eligible patients.
Against that background, the key question is whether HBOT adds anything for patients already on optimal medical therapy, and the small studies have not controlled for it. A heart-failure cardiologist who knows your full regimen and functional status is the right person to judge whether HBOT has any role in a specific case. The 4.16% ejection-fraction signal above comes from coronary-disease patients after revascularization, not from a heart-failure population, and should not be generalized to heart failure.
What About HBOT After Cardiac Surgery?
Cardiac surgery is physiologically demanding: the heart-lung bypass machine can trigger systemic inflammation and micro-emboli, and recovery involves healing the sternotomy and surgical incisions. HBOT has been explored as an adjunct here for its anti-inflammatory and tissue-healing effects, but the evidence is limited to small studies and it is not a standard post-surgery protocol. The most plausible role is in patients with delayed sternal healing or wound complications, where the wound-healing rationale is strongest. Our page on HBOT for wound healing covers that mechanism, including how smoking blunts the angiogenic response.
How Does HBOT Relate to Peripheral Vascular Disease?
Many people with heart disease also have peripheral artery disease (PAD), reduced blood flow to the legs and feet. HBOT for PAD-related non-healing wounds is a distinct application from cardiac HBOT, and it rests on better evidence: improving oxygen delivery to ischemic tissue and stimulating new blood vessels. Patients with concurrent heart disease who receive HBOT for PAD wounds need cardiac monitoring during sessions and clearance from their cardiologist. Diabetes often sits alongside both conditions, and our page on HBOT for diabetes covers the vascular complications HBOT is used for.
Is HBOT Safe for Cardiac Patients?
HBOT is not appropriate for every cardiac patient. The pressurization process and the physical demands of chamber entry are unsuitable for anyone with severe cardiac instability, uncontrolled arrhythmias, or decompensated heart failure. At therapeutic pressures (2.0 ATA and above), HBOT produces a mild, temporary drop in heart rate and a small rise in peripheral vascular resistance from oxygen-induced vasoconstriction, effects that are usually modest and well tolerated but warrant monitoring in hypertensive or arrhythmia-prone patients.
Ejection-fraction thresholds and stability criteria should be discussed with your cardiologist before any HBOT is considered. Our side effects and contraindications guide covers cardiac-specific points, and the session guide explains what the process physically involves. For context on where HBOT does have regulatory backing, see the FDA-cleared indications for HBOT, which do not include primary heart disease.
Can HBOT replace cardiac medication?
No. There is no evidence that HBOT substitutes for any established cardiac medication, whether for heart failure, arrhythmia, or coronary artery disease. Guideline-backed drugs such as beta-blockers, ACE inhibitors, SGLT2 inhibitors, and antiplatelet therapy have mortality evidence that HBOT does not. At most, HBOT is a possible adjunct under specialist supervision, not an alternative (Bennett et al., 2015).
Is HBOT safe after a heart attack?
In stable post-heart-attack patients, HBOT may be considered with cardiologist clearance. In the acute or immediate period after a heart attack, it is not generally used outside specific research protocols, and the older HOT-MI trial that studied that setting predates modern stenting (Stavitsky et al., 1998). Stability of the cardiac condition is the prerequisite for any HBOT consideration.
Does HBOT affect heart rate?
Yes, modestly. Therapeutic HBOT typically produces a mild reduction in heart rate during the session, part of the cardiovascular reflex response to high oxygen (Wunderlich et al., 2017). This is well tolerated in most patients but needs monitoring in those with arrhythmias or pacemakers, and pacemaker compatibility with the hyperbaric environment should be confirmed before treatment.
Where can I find a cardiologist familiar with HBOT?
Major academic medical centers and hospitals with hyperbaric medicine programs are the most likely places to find cardiologists and hyperbaric physicians who coordinate on cardiac patients. The Undersea and Hyperbaric Medical Society maintains a directory of accredited hyperbaric programs at uhms.org.
Sources
- Bennett MH, Lehm JP, Jepson N. “Hyperbaric oxygen therapy for acute coronary syndrome.” Cochrane Database of Systematic Reviews, 2015;(7):CD004818. doi:10.1002/14651858.CD004818.pub4
- Putra Pramana KAA, Sintya Dwi Cahyani NGAM, Pintaningrum Y. “Effect of hyperbaric oxygen therapy on LV function in CAD patients after reperfusion based on echo: a meta-analysis.” British Journal of Cardiology, 2025;32(2):017. doi:10.5837/bjc.2025.017
- Stavitsky Y, Shandling AH, Ellestad MH, et al. “Hyperbaric oxygen and thrombolysis in myocardial infarction: the ‘HOT MI’ randomized multicenter study.” Cardiology, 1998;90(2):131-136. PMID 9778551
- Wunderlich T, Frey N, Kähler W, et al. “Influence of hyperoxia on diastolic myocardial and arterial endothelial function.” Undersea and Hyperbaric Medicine, 2017;44(6):521-533. PMID 29281189
- Cooper JS, Hanley ME, Hendriksen S, et al. “Hyperbaric Cardiovascular Effects.” StatPearls. StatPearls Publishing. NBK482231
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
